A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma

A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma

Tolerance toward tumor antigens, which are shared by normal tissues, have often limited the efficacy of cancer vaccines. However, wild type epitopes can be tweaked to activate cross-reactive T-cell clones, resulting in antitumor activity. The design of these analogs (i.e., heteroclitic peptides) can...

Full description

Bibliographic Details
Main Authors: Cristian Capasso, Aniket Magarkar, Victor Cervera-Carrascon, Manlio Fusciello, Sara Feola, Martin Muller, Mariangela Garofalo, Lukasz Kuryk, Siri Tähtinen, Lucio Pastore, Alex Bunker, Vincenzo Cerullo
Format: Article
Language:English
Published: Taylor & Francis Group 2017-09-01
Series:OncoImmunology
Subjects:
cancer vaccine
heteroclitic peptides
immunotherapy
in silico
prediction servers
tumor antigens
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1319028

Internet

http://dx.doi.org/10.1080/2162402X.2017.1319028

Similar Items